智通财经APP讯，泰达生物(08189)发布公告，配售协议的所有条件已获达成，而配售事项已于2025年5月8日完成。根据配售协议的条款及条件，配售代理已成功按每股配售股份0.375港元的配售价向不少于六名承配人配售合共1.035亿股配售股份，相当于紧随配售事项完成后公司经配发及发行所有配售股份扩大后已发行股本约4.85%及已发行H股约7.21%。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.